Mr Peng Tan

Consultant Oncoplastic Breast Surgeon

MBBS, MSC, MRSC, DIC, PHD, MD, FRCS (GEN SURG)

Mr Peng Tan is a Consultant Oncoplastic Breast Surgeon. He graduated with MBBS and MSc degrees, from Imperial College London, in 1995 and was in the Basic Surgical Training Programmes in Cambridge and London leading to a MRCS Diploma.

Mr Tan was then awarded with the MRC (UK) Fellowship researching into genetic manipulation of immune and vascular cells of which culminated in PhD and MD degrees with University of London.

He has been awarded with multiple awards by many learning societies and the Royal College of Surgeons. His work was recognised by the British Transplantation Society and the International Transplantation Society with an award of the Roy Calne Young Investigators Award and the New Key Opinion Leader of Tomorrow Award. The Royal of Surgeons also recognised his contribution with an award of Syme Medal. In addition, he was also won multiple travelling awards with the British Immunology Society and Pfizers Academy.

Mr Tan then went to Oxford University to become its Lecturer in Surgery and completed his Higher Surgical Training Programmes with the Oxford School of Surgery. In Oxford, he was awarded with Sir Peter Morris Surgeon Scientist to start up his research programme on the development of a vaccine for breast cancer. From Oxford, he went onto further sub-speciality training in Oncoplastic Surgery at the Royal Marsden Foundation Trust and the Imperial College Healthcare NHS Trust.

He then completed his General Surgery and Oncoplastic Breast Training, leading to his fellowship with the Royal College of Surgeons.Currently, he is a Consultant Oncoplastic Breast Surgeon at Royal Free NHS Foundation Trust for his NHS practice prior to that he held a similar position at Whittington Hospital NHS Trust for 5 years.

Specialities

  • Oncology
  • Breast Surgery

Clinical Interests

Mr Tan has established a highly reputable clinical practice in oncoplastic breast surgery techniques over years within University teaching hospitals in London and Oxford with tertiary referrals of complex cases and second opinions.

He has an established practice in symptomatic and screen-detected breast cancers reviewing over 250 patients annually and has extensive experience in types of immediate breast reconstruction after mastectomy for cancer and complex types of breast conserving mammoplasties (over 250 cases) used in larger cancer or more than one breast cancer in the same breast in order to optimize cosmetic results.

Temporary two-stage breast reconstructive approaches are offered to the patients requiring radiotherapy after mastectomy. Mr Tan facilitates immediate mirco-vascular breast reconstructions working alongside the best Consultant Plastic Surgeon.

He has a large photographic database for his breast reconstruction results for the purposes of informing individual patients outcomes.

Procedures Offered

  • Breast lump investigation
  • Single-dose intraoperative radiotherapy (SD-IORT) for early stage breast cancer
  • Sentinel lymph node biopsy and lymph node removal
  • Breast lump removal
  • Breast reconstruction following mastectomy
  • Cancer tests
  • Mastectomy
  • Breast cancer diagnosis (clinical and imaging using ultrasound)
  • Breast conserving surgery using cosmetic techniques
  • Intra-operative radiotherapy at time of surgery to avoid whole breast radiotherapy
  • Immediate Implant and biological sling breast reconstruction
  • Breast reconstruction
  • Sentinel lymph node diagnosis using dual localisation

Clinical interests

Mr Tan has established a highly reputable clinical practice in oncoplastic breast surgery techniques over years within University teaching hospitals in London and Oxford with tertiary referrals of complex cases and second opinions.

He has an established practice in symptomatic and screen-detected breast cancers reviewing over 250 patients annually and has extensive experience in types of immediate breast reconstruction after mastectomy for cancer and complex types of breast conserving mammoplasties (over 250 cases) used in larger cancer or more than one breast cancer in the same breast in order to optimize cosmetic results.

Temporary two-stage breast reconstructive approaches are offered to the patients requiring radiotherapy after mastectomy. Mr Tan facilitates immediate mirco-vascular breast reconstructions working alongside the best Consultant Plastic Surgeon.

He has a large photographic database for his breast reconstruction results for the purposes of informing individual patients outcomes.

Research interests

Mr Tan’s research interests embrace both basic and applied molecular biology in the context of cancer, transplantation and vascular biology, with an increasing emphasis on the translational research – obesity biology in areas of adiponectin & its signaling pathways; tumour immunology in the area of breast cancer; gene therapy vector development; induction of immunological tolerance by manipulating endothelial and dendritic cells; dendritic cell biology in the aspects of its co-stimulation, internalization of antigen, antigenic presentation & signaling transduction; vascular biology; corneal transplantation studying corneal rejection model and corneal cellular biology & effect diabetes on antigenic presentation.

Evolving role of adiponectin in cancer – controversies and update (Review Article)A Katira, PH Tan (Senior Authorship) Cancer Biology and Medicine 2016 Mar;13(1):101-19. doi: 10.28092/j.issn.2095-3941.2015.0092.

Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity (Review Article) A Katira, PH Tan (Senior Authorship) Expert Opinion Therapeutic Targets May 2015 19(8):1105-25

Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity (Original Research Article) PH Tan, HE Tyrrell, L Gao, D Xu, J Quan, D Gill, L Rai, Y Ding, G Plant, Y Chen, JZ Xue, AI Handa, M Greenall, K Walsh, SA Xue Canncer Res 2014 Sept; 74(20): 1-12

Mesenchymal stem cells differentially mediate regulatory T cells and conventional effector T cells to protect fully allogeneic islet grafts in mice (Original Research Article) DM Xu, XF Yu, D Zhang, MX Zhang, JF Zhou, PH Tan, YC Ding Diabetologia 2012 Apr; 55(4):1091-102

Vascular endothelial growth factor receptors and cancer therapeutic targeting: where do we go from here? (Review Article) D Bruce, PH Tan (Senior Authorship) Cell Communication & Adhesion 2011 Oct; 18(5): 85-103

Controlling the cost of breast cancer (Review Article) D Gill, D Bruce, PH Tan (Senior Authorship) Eur J Cancer Care (Engl) 2011 Nov; 20(6): 703-7

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? (Review Article) D Bruce, PH Tan (Senior Authorship) Expert Opinion on Investigational Drugs 2011 Oct; 20(10): 1413-34

Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target (Review Article) D Gill, PH Tan (Senior Authorship) Expert Opinion on Therapeutic Target 2010 Aug; 14(8): 797-824

Manipulation of indoleamine 2, 3-dioxygenase (IDO); a novel therapeutic target for treatment of diseases (Review Article) PH Tan, AK Bharath Expert Opinion on Therapeutic Target 2009 Aug; 13(8): 987-1012

Targeting gene delivery to activated vascular endothelium using anti-E/P selectin antibody linked to PAMAM dendrimers (Original Research Article) S Theoharis, U Krueger, PH Tan, DO Haskard, M Weber, AJ George Journal of Immunological Methods 2009 Apr 15; 343(2): 79-90

Manipulation of indoleamine 2, 3-dioxygenase (IDO) for clinical transplantation; promises and challenges (Review Article) J Quan*, PH Tan* (*Joint First), A MacDonald, PJ Friend Expert Opinion on Biological Therapy 2008 Nov; 8(11): 1705-19

Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics (Review Article) PH Tan, AS Lota Expert Opinion on Pharmacotherapy 2008 Oct; 9(15): 2639-60

More trouble ahead; is gene therapy coming of age? (Review Article) PH Tan, SE Janes, AI Handa, PJ Friend Expert Opinion on Biological Therapy 2008 May; 8(5): 1-7

Modulation of the immune response by targeting endothelial cells (Review Article) M Manunta, PH Tan, AJ George Current Medicinal Chemistry – Anti-Inflammatory & Anti-Allergy Agents 2007 May; 6(2): 171-181

Gene delivery to vascular endothelium using chemical vectors; implications for cardiovascular gene therapy (Review Article) S Theoharis, M Manunta, PH Tan (Senior Authorship) Expert Opinion on Biological Therapy 2007 May; 7(5): 627-43

Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design (Original Research Article) PH Tan*, SA Xue* (*Joint first), B Wei, A Holler, RH Voss, AJ George Molecular Medicine 2007 Mar-Apr; 13(3-4): 216-26

Knockdown of mouse VCAM-1 by vector-based siRNA (Original Research Article) AK Alam, O Florey, M Weber, RG Pillai, C Chan, PH Tan, RI Lechler, MO McClure, DO Haskard, AJ George Transplant Immunology 2006 Nov; 16(3-4): 185-93

Aspirin-treated human dendritic cells upregulate ILT-3 and induce hypo-responsiveness and regulatory activity in responder T cells (Original Research Article) M Buckland, CB Jago, H Fazekasova, K Scott, PH Tan, AJ George, R Lechler, G Lombardi American Journal of Transplantation 2006 Sep; 6(9): 2046-59

Gene therapy for clinical transplantation; where do we stand in 2006? (Review Article) PH Tan, AJ George, AI Handa Discovery Medicine 2006 Aug; 6(34): 153-56

Gene therapy for transplantation with viral vectors- how much of the promise has been realized? (Review Article) PH Tan, PL Tan, AJ George, CLH Chan Expert Opinion on Biological Therapy 2006 Aug; 6(8): 759-72

Gene delivery by dendrimers operates via different pathways in different cells, but is enhanced by the presence of caveolin (Original Research Article) M Manunta, B Nichols, PH Tan, P Sagoo, JE Harper, AJ George Journal of Immunological Methods 2006 Jul; 314(1-2): 134-46

Strategies to improve non-viral vectors- potential applications in clinical transplantation (Review Article) PH Tan, CLH Chan, AJ George Expert Opinion on Biological Therapy 2006 Jun; 6(6): 619-30

Expression of indoleamine 2, 3-dioxygenase (IDO) on endothelial cells: implications for control of alloresponses (Original Research Article) SC Beutelspacher*, PH Tan*(*Joint First), MO McClure, DF Larkin, RI Lechler, AJ George American Journal of Transplantation 2006 Jun; 6(6): 1320-30

Fat necrosis of the breast- a review (Review Article) PH Tan, LM Lai, EV Carrington, AS Opaluwa, KH Ravikumar, N Chetty, V Kaplan, CJ Kelley, ED Babu Breast 2006 Jun; 15(3): 313-8

Function of indoleamine 2, 3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression (Original Research Article) SC Beutelspacher, R Pillai, MP Watson, PH Tan, J Tsang, MO McClure, AJ George, DF Larkin European Journal of Immunology 2006 Mar; 36(3): 690-700

Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy (Original research article) PH Tan, SA Xue, M Manunta, SC Beutelspacher, H Fazekasova, AK Alam, MO McClure, AJ George Arteriosclerosis, Thrombosis, and Vascular Biology 2006 Mar; 26(3): 462-7

Delivery of oligodeoxynucleotides into human saphenous veins: the adjunct effect of ultrasound and microbubbles (Original Research Article) T Kodama, PH Tan, I Offiah, T Partridge, T Cook, AJ George, MJ Blomley Ultrasound in Medicine and Biology 2005 Dec; 31(12): 1683-1691

The evolving role of gene-based treatment in surgery (Review Article) PH Tan, CLH Chan, C Chan, AJ George British Journal of Surgery 2005 Dec; 92(12): 1466-1480

Comparison of several viral vectors for gene therapy of corneal endothelial cells (Original Research Article) SC Beutelspacher, N Serbecic, PH Tan, MO McClure Ophthalmologe 2005 Dec; 102(12): 1168-74

Creation of tolerogenic human dendritic cells via intracellular CTLA4- a novel strategy with potential in clinical immunosuppression (Plenary Article – Original Research Article) PH Tan, JB Yates, SA Xue, C Chan, WJ Jordan, JE Harper, MP Watson, R Dong, MA Ritter, RI Lechler, G Lombardi, AJ George Blood 2005 Nov; 106(9): 2936-2943

Tolerant T cells display impaired trafficking (Original Research Article) V Mirenda, O Millington, RI Lechler, D Scott, MP Hernandez-Fuentes, J Read, PH Tan, AJ George, P Garside, FM Marelli-Berg European Journal of Immunology 2005 July, 33(7), 2146–2156

Inhibition of NF[kappa]B and oxidative pathways in human dendritic cells by anti-oxidative vitamins generates regulatory T cells (Original Research Article) PH Tan, P Sagoo, C Chan, JB Yates, J Campbell, SC Beutelspacher, BM Foxwell, G Lombardi, AJ George, Journal of Immunology 2005 Jun; 174(12): 7633-44

Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction (Original Research Article) SC Beutelspacher, N Ardjomand, PH Tan, GS Patton, DF Larkin, AJ George, MO McClure Experimental Eye Research 2005 Jun; 80(6): 787-94

Modulation of human dendritic cell function following transduction with viral vectors: implications for gene therapy (Original Research Article) PH Tan, SC Beutelspacher, SA Xue, YH Wang, P Mitchell, JC McAlister, HJ Stauss, MA Ritter, DF Larkin, MO McClure, G Lombardi, AJ George Blood 2005 May; 105(10): 3824-32

An efficient, non-viral alternative to viral vectors for transfection of human dendritic cells: a potential tool for clinical vaccination (Original Research Article) PH Tan, SC Beutelspacher, YH Wang, MO McClure, MA Ritter, G Lombardi, AJ George Molecular Therapy 2005 May; 11(5): 790-80

Gene delivery by dendrimers operates via a cholesterol-dependent pathway (Original Research Article) M Manunta, PH Tan, P Sagoo, K Kashefi, AJ George Nucleic Acids Research 2004 May; 32(9): 2730-9

A low dose of ethanol modulate toxic effect of iron-overloading in the liver (Original Research Article) SC Beutelspacher, N Serbecic, PH Tan, M Mehrabi, P Nielson, Y Yamane Journal of Nutritional Science and Vitaminology 2004 Apr; 50(2): 78-86

Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells (Original Research Article) PH Tan, C Chan, SA Xue, R Dong, B Anathesayanan, M Manunta, C Kerouedan, NJ Cheshire, JH Wolfe, DO Haskard, KM Taylor, AJ George Atherosclerosis 2004 Apr; 173(2): 171-83

Modulation of co-stimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection (Original Research Article) N Ardjomand, JC McAlister, NJ Rogers, PH Tan, AJ George, DF Larkin Investigative Ophthalmology Visual Science 2003 Sep; 44(9): 3899-905

Antibody-directed gene delivery to endothelium (Original Research Article) PH Tan, M Manunta, N Ardjomand, SA Xue, DFP Larkin, DO Haskard, KM Taylor, AJ George Journal of Gene Medicine 2003 Apr; 5(4): 311-23

Transferrin receptor-mediated gene transfer to corneal endothelium (Original Research Article) PH Tan, WJ King, D Chen, HM Awad, M Mackett, RI Lechler, DF Larkin, AJ George Transplantation 2001 Feb; 71(4): 552-60

Gene delivery to the corneal endothelium (Review Article) AJ George, CV Arancibia-Corcarno, HM Awad, RM Cromer, Z Fehevari, WJ King, M Hassan, T Huddle, C Lebosse, F Mirza, HB Oral, SA Rayner, PH Tan, E Tay, DF Larkin American Journal of Respiratory and Critical Care Medicine 2000 Oct; 162(4 Pt 2): S194-200

Publication of letters & case reports:

The Transplantation Society – New Key Opinion Leaders of Tomorrow 2006 (Meeting Report) PH Tan, K Giles, PL Tan Expert Opinion on Biological Therapy 2007 Jan; 7(1): 149-52

World Transplant Congress. Boston, Massachusetts, USA, 22 – 27 July 2006 (Congress Report) PH Tan Expert Opinion on Biological Therapy 2006 Oct; 6(10): 1061-5

9th American Society of Gene Therapy Annual Meeting (Congressional Report) PH Tan Expert Opinion on Biological Therapy 2006 Aug; 6(8): 839-42

American Transplant Congress 2005 (Congress Report) PH Tan Immunology News 2005 Aug; 12(3): 24-6

Like to book an appointment?

Fill out the contact form below or call us on
020 7317 7751 to speak with a member of our team

020 7317 7751 Book a Consultation